Cutaneous melanoma skin cancer
Conditions
Interventions
Subjects will receive 2 sachets of 10 g WholeFiber per day for 6 weeks (equals 
17 g fiber). In the first week the dose will be 10 g/day, to get used to the product.
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
16 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Age >=18 years; • The participant understands the study and can provide written informed consent; • The participant received surgical treatment of an intermediate to high-risk cutaneous melanoma (T2a, T2b, T3a, T3b, T4a, T4b, N0 or N+, M0, Stage IV with no evidence of M+ disease); • Being able to read and speak Dutch; • Willing to come to the UMCG for practical reasons (visiting the study site); • Willing to continue their regular lifestyle patterns during the study.
Exclusion criteria
Exclusion criteria: • Receiving concurrent adjuvant treatment, adjuvant treatment after the study period is allowed. • Having a medical history that may impact study outcomes, such as a diagnosis of diabetes mellitus type 2, heart disease, renal disease, autoimmune disease; • Any clinically significant or unstable medical disorder involving the gut, including celiac disease, inflammatory bowel disease, short-bowel syndrome or acute/chronic pancreatitis; • Having an ileostomy or colostomy, as this greatly impacts bowel function and gut microbial composition; • Use of antibiotics in the 3 months prior participation in the study; • Use of prednisolone or other immunosuppressive medication; • Use of tube feeding or sib-feeding; • Being pregnant or lactating; • Participation in another interventional study at the same time; • Unable or unwilling to comply to study rules.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of a high fiber prebiotic vegetable (WholeFiber) for 6 weeks on fecal SCFA levels in intermediate to high-risk cutaneous melanoma patients, with no concurrent adjuvant treatment. HPLC ion chromatography system (Metrohm AG, Herisau, Switzerland) will be used to determine the levels of SCFA. The concentrations of SCFA; butyrate, propionate, and acetate will be measured with a conductivity detector. SCFA will be measured at baseline, halfway intervention and after 6 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Discovering the gut microbial composition changes measured in intermediate to high-risk cutaneous melanoma patients with no concurrent adjuvant treatment, after using WholeFiber for 6 weeks. This analysis will be based on whole genome sequencing of fecal samples performed at the UMCG according to standardized protocol. Exploring the effect of WholeFiber use for 6 weeks on immune functioning, stool patterns, fecal calprotectin levels and side effects in this patient group. Peripheral blood mononuclear cells (PBMCs) and bloodplasma will be isolated to be able to identify hypothesized changes in immune cell composition. Fecal calprotectin will be determined using the respective ELISA kit (Thermo Fisher Scientific). Calprotectin is released when neutrophils enter the gut wall and are activated during the inflammatory process. Lastly, eating patterns, fiber intake before the start of the studyperiod, stool patterns and side effects will be identified using - Food Frequency Questionnaire - Bristol Stool Scale - Gastrointestinal Symptoms Rating Scale - Health Related Quality of Life Questionnaire | — |
Countries
Netherlands
Contacts
Public ContactG.A.P. Hospers
Universitair Medisch Centrum Groningen
Outcome results
None listed